Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone45-3326-8383
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$79.30 million
Profitability
Miscellaneous
Employees419
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions
What is BAVARIAN NORDIC/S's stock symbol?
BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY."
How were BAVARIAN NORDIC/S's earnings last quarter?
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) posted its quarterly earnings data on Thursday, August, 15th. The company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.03. The company had revenue of $15.26 million for the quarter, compared to the consensus estimate of $19.80 million. BAVARIAN NORDIC/S had a negative return on equity of 12.47% and a negative net margin of 42.42%. View BAVARIAN NORDIC/S's Earnings History.
When is BAVARIAN NORDIC/S's next earnings date?
Has BAVARIAN NORDIC/S been receiving favorable news coverage?
Media headlines about BVNRY stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BAVARIAN NORDIC/S earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for BAVARIAN NORDIC/S.
Who are some of BAVARIAN NORDIC/S's key competitors?
Some companies that are related to BAVARIAN NORDIC/S include Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Sangamo Therapeutics (SGMO), Alector (ALEC), Editas Medicine (EDIT) and Aerie Pharmaceuticals (AERI).
What other stocks do shareholders of BAVARIAN NORDIC/S own?
Who are BAVARIAN NORDIC/S's key executives?
BAVARIAN NORDIC/S's management team includes the folowing people:
- Dr. Paul Chaplin, CEO & Pres (Age 52)
- Mr. Henrik Juuel, CFO & Exec. VP (Age 54)
- Mr. Henrik Birk, COO & Exec. VP (Age 45)
- Dr. Tommi Kainu, Exec. VP & Chief Bus. Officer (Age 46)
- Dr. Christopher R. Heery, Chief Medical Officer
How do I buy shares of BAVARIAN NORDIC/S?
Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BAVARIAN NORDIC/S's stock price today?
One share of BVNRY stock can currently be purchased for approximately $8.83.
How big of a company is BAVARIAN NORDIC/S?
BAVARIAN NORDIC/S has a market capitalization of $855.99 million and generates $79.30 million in revenue each year. The company earns $-57,330,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. BAVARIAN NORDIC/S employs 419 workers across the globe.View Additional Information About BAVARIAN NORDIC/S.
What is BAVARIAN NORDIC/S's official website?
How can I contact BAVARIAN NORDIC/S?
BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected]
MarketBeat Community Rating for BAVARIAN NORDIC/S (OTCMKTS BVNRY)
MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC/S and other stocks. Vote "Outperform" if you believe BVNRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVNRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
